GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » Debt-to-Revenue

Aptahem AB (XSAT:APTA) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptahem AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Aptahem AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Aptahem AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Aptahem AB Debt-to-Revenue Historical Data

The historical data trend for Aptahem AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB Debt-to-Revenue Chart

Aptahem AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Aptahem AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Aptahem AB's Debt-to-Revenue

For the Biotechnology subindustry, Aptahem AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptahem AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptahem AB's Debt-to-Revenue falls into.



Aptahem AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptahem AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Aptahem AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Aptahem AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptahem AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptahem AB (XSAT:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB (XSAT:APTA) Headlines

No Headlines